



Monitoring Parameters

- Lymphocyte, neutrophil, platelet counts, and Hb
- LFTs
- Renal function (baseline and periodically thereafter)
- Signs/symptoms of infections (including tuberculosis) during and after therapy
- Lipids (12 weeks after therapy initiation and periodically thereafter)
- Viral hepatitis (prior to initiating therapy in accordance with clinical guidelines)
- Tuberculosis (TB) infection (latent TB) prior to initiating therapy
- Abdominal symptoms (in patients at increased risk for GI perforation)
- Skin examinations (periodically, in patients at increased risk for skin cancer)

Reference

Baricitinib Drug Information, UpToDate [July 2026]

Intyma[®]
Baricitinib



Baricitinib



Description

Intyma® contains baricitinib as an active substance.



Dosage Forms

The film-coated tablets are supplied in 2 mg and 4 mg strengths.



Indications

Baricitinib is indicated for the treatment of:

- **Alopecia areata:** Treatment of severe alopecia areata in adults.
- **Rheumatoid arthritis:** Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor blockers.
- **Atopic dermatitis:** Moderate to severe (off-label use)
- **Interstitial lung disease associated with mixed connective tissue disease** (off-label use)



Dosing: Adults

- **Alopecia areata**
Initial: 2 mg once daily; if response is inadequate, the dose may be increased to 4 mg once daily.
- **Rheumatoid arthritis**
2 or 4 mg once daily. In patients receiving 4 mg once daily, the dose may be reduced to 2 mg once daily once an adequate response is achieved.
- **Atopic dermatitis, moderate to severe (off-label use):**
Initial: 2 or 4 mg once daily. In patients receiving 4 mg once daily, the dose may be reduced to 2 mg once daily once an adequate response is achieved.
- **Interstitial lung disease associated with mixed connective tissue disease (off-label use):** 2 mg once daily



Administration

May be administered with or without food. For patients unable to swallow tablets whole, tablets may be dispersed in water.



Adverse Reactions

>10%

Infections: 29% (serious infections: 1%)

Respiratory: Upper respiratory tract infection (16% to 21%)



Reproductive Considerations

Pregnancy planning and effective contraception should be discussed with patients who could become pregnant. Consider discontinuing baricitinib 1 month prior to conception.



Pregnancy Considerations

Baricitinib is expected to cross the placenta, and animal data suggest potential fetal harm; human pregnancy data are limited.



Breastfeeding Considerations

It is not known whether baricitinib is present in breast milk, but transfer may be expected based on its molecular weight. Because of the potential risk of serious adverse effects in the infant, breastfeeding is not recommended during treatment and for 4 days after the last dose.



Contraindications

There are no contraindications listed in the manufacturer's US labeling.